{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:46:44Z","timestamp":1788788804995,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clml.2020.12.010","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T12:47:49Z","timestamp":1608209269000},"page":"e334-e347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed\/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes"],"prefix":"10.1016","volume":"21","author":[{"given":"Sobia","family":"Aamir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9471-735X","authenticated-orcid":false,"given":"Muhammad Yasir","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-5118","authenticated-orcid":false,"given":"Farhan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ashar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoia Ehsan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.12.010_bib1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.12.010_bib2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.12.010_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2007-1025528","article-title":"[Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies]","volume":"202","author":"Ludwig","year":"1990","journal-title":"Klin Pediatr"},{"key":"10.1016\/j.clml.2020.12.010_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"M\u00f6ricke","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.12.010_bib7","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.12.010_bib8","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.010_bib9","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.12.010_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2020.12.010_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2020.12.010_bib12","doi-asserted-by":"crossref","first-page":"e26909","DOI":"10.1002\/pbc.26909","article-title":"Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Oskarsson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2020.12.010_bib13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1177\/1078155218817816","article-title":"FLAG\/FLAG-IDA regimen for children with relapsed\/refractory acute leukemia in the era of targeted novel therapies","volume":"25","author":"Mustafa","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2020.12.010_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03007995.2017.1384373","article-title":"Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"34","author":"Crotta","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2020.12.010_bib15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.010_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","article-title":"Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia","volume":"9","author":"Tomuleasa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2020.12.010_bib17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clml.2020.12.010_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.clml.2020.12.010_bib19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2020.12.010_bib20","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bbmt.2018.12.308","article-title":"Directed chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Anagnostou","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2020.12.010_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2020.12.010_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.clml.2020.12.010_bib23","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL","volume":"134","author":"Curran","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib24","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2020.12.010_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.010_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.12.010_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood-2018-99-114346","article-title":"Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor modified T cells in a phase i study targeting pediatrics with acute lymphoblastic leukemia","volume":"132","author":"Ma","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib29","doi-asserted-by":"crossref","first-page":"v360","DOI":"10.1093\/annonc\/mdx373.014","article-title":"ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL)","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.12.010_bib30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2019-130060","article-title":"Cytogenetic characteristics and outcomes of patients receiving CTL019 car T cell therapy","volume":"134","author":"Leahy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib31","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/j.clml.2019.07.186","article-title":"Autologous CD19-CAR T-cells for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients: an initial report from an institutional phase I\/II study","volume":"19","author":"Talleur","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.12.010_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-019-02771-2","article-title":"Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"111","author":"Hiramatsu","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.12.010_bib33","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2018-99-110164","article-title":"Minimal change in CAR T cell manufacturing can impact in expansion and side effect of the CAR T cell therapy","volume":"132","author":"Ceppi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2019-129821","volume":"134","author":"Del Bufalo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib35","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1182\/blood-2019-131123","article-title":"Safety and efficacy of tisagenlecleucel (CTL019) in B-cell acute lymphoblastic leukemia in children, adolescents and young adults: the French experience","volume":"134","author":"Dourthe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.010_bib36","first-page":"270","article-title":"[Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes]","volume":"40","author":"Zuo","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2020.12.010_bib37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/08880018.2019.1704325","article-title":"Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1\/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children","volume":"37","author":"Shen","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2020.12.010_bib38","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.010_bib39","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2020.12.010_bib40","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.12.010_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hon.2682","article-title":"Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Yang","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.12.010_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clml.2020.12.010_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","article-title":"Monocyte lineage\u2013derived IL-6 does not affect chimeric antigen receptor T-cell function","volume":"19","author":"Singh","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2020.12.010_bib44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014an expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clml.2020.12.010_bib45","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:29Z","timestamp":1730529389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020310168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2152265020310168"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed\/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}